Patients with emphysema assured of access to disease slowing Respreeza drug

Patients with genetic emphysema have been assured of continued access to the only drug shown to slow its progression until at least the end of the year.

Johnny Hannan, who has Alpha-1 antitrypsin deficiency, a disease that can cause severe lung and liver damage, said Respreeza will be available to 19 patients until next December, or until a new drug trial starts, whichever occurs first.